22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ALNYLAM PHARMACEUTICALS INC. › 2024-2025

ALNYLAM PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Reported items
  • 591Asset managers, any item
  • 5,798Fund votes
  • May 8, 2025Meeting date

Results at a glance

Meeting of May 8, 2025: 8 items on ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 13, 2025: 4 elected · 4 approved.

Dissent

Notable dissent: 1 director (12.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALNYLAM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ALNYLAM PHARMACEUTICALS INC.

These tallies are ALNYLAM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALNYLAM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 8, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Carolyn R. Bertozzi, Ph.D. 108,200,09810,440,70824,081 --4,826,451 91%Elected—
Elect Director: Margaret A. Hamburg, M.D. 108,041,42010,601,23022,237 --4,826,451 91%Elected—
Elect Director: Colleen F. Reitan 111,919,8646,734,58510,438 --4,826,451 94%Elected—
Elect Director: Amy W. Schulman 103,753,05514,370,696541,136 --4,826,451 88%Elected—
The terms of office of the following directors continued after the Annual Meeting: Dennis A. Ausiello, M.D. 111,515,5537,120,85728,477 --4,826,451 94%Approved—
3. Company's Second Amended and Restated 2018 Stock Incentive Plan 114,044,4964,590,66129,730 --4,826,451 96%Approved—
4. In a non-binding advisory vote, the compensation of the Company's named executive officers 111,725,9076,909,70629,274 --4,826,451 94%Approved—
5. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025 117,032,9476,405,21553,176 --0 95%Approved—

Source: ALNYLAM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 13, 2025 — read the filing on EDGAR.

How asset managers voted at the ALNYLAM PHARMACEUTICALS INC. 2024-2025 meeting

591 asset managers disclosed a vote on at least one ALNYLAM PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ALNYLAM PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Amy W. Schulman

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 103,753,055AGAINST: 14,370,696
Details: description as filed, official tally, votes by 130 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Amy W. Schulman”): 103,753,055 for, 14,370,696 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 130 asset managers below reported 66,638,547 for, 7,187,268 against, 354,407 abstained.

FOR
FOR: 66,638,547AGAINST: 7,187,268ABSTAIN: 354,407
Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1951 00For
Fidelity13,243,1540 00For
T. Rowe Price05,284,540 00Against
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National368,014432,844 00Mixed
New York Life734,7030 00For
TIAA684,0000 00For
State Street1,098613,124 00Against
Charles Schwab531,7400 00For
Invesco058,830 344,4100Mixed
Prudential/PGIM252,0730 00For
MassMutual26,477193,472 00Mixed
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable141,25647,134 00Mixed
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).

Elect Director: Carolyn R. Bertozzi, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 108,200,098AGAINST: 10,440,708
Details: description as filed, official tally, votes by 130 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carolyn R. Bertozzi, Ph.D.”): 108,200,098 for, 10,440,708 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 130 asset managers below reported 67,688,379 for, 6,487,177 against, 4,666 abstained.

FOR
FOR: 67,688,379AGAINST: 6,487,177ABSTAIN: 4,666
Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1951 00For
Fidelity13,243,1540 00For
T. Rowe Price05,284,540 00Against
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National368,014432,844 00Mixed
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,2220 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM252,0730 00For
MassMutual26,477193,472 00Mixed
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable141,25647,134 00Mixed
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).

Elect Director: Colleen F. Reitan

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 111,919,864AGAINST: 6,734,585
Details: description as filed, official tally, votes by 130 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Colleen F. Reitan”): 111,919,864 for, 6,734,585 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 130 asset managers below reported 71,353,982 for, 2,821,574 against, 4,666 abstained.

FOR
FOR: 71,353,982AGAINST: 2,821,574ABSTAIN: 4,666
Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1951 00For
Fidelity13,243,1540 00For
T. Rowe Price2,620,5602,663,980 00Mixed
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National800,8580 00For
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,2220 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM252,0730 00For
MassMutual215,5094,440 00For
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable141,25647,134 00Mixed
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).

Elect Director: Margaret A. Hamburg, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 108,041,420AGAINST: 10,601,230
Details: description as filed, official tally, votes by 130 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Margaret A. Hamburg, M.D.”): 108,041,420 for, 10,601,230 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 130 asset managers below reported 67,688,602 for, 6,486,954 against, 4,666 abstained.

FOR
FOR: 67,688,602AGAINST: 6,486,954ABSTAIN: 4,666
Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1951 00For
Fidelity13,243,1540 00For
T. Rowe Price05,284,540 00Against
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National368,014432,844 00Mixed
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,2220 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM252,0730 00For
MassMutual26,477193,472 00Mixed
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable141,25647,134 00Mixed
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).

To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.

No official matchCORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: votes by 127 asset managers

The 127 asset managers below reported 71,426,204 for, 2,681,353 against, 4,666 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 71,426,204AGAINST: 2,681,353ABSTAIN: 4,666
Largest asset managers voting on “To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,757,81544,381 00For
Fidelity13,243,1540 00For
T. Rowe Price5,284,5400 00For
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan01,384,836 00Against
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National520,660280,198 00Mixed
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,17250 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM86,556165,517 00Mixed
MassMutual193,47226,477 00Mixed
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes0192,849 00Against
CARILLON SERIES TRUST190,4890 00For
Equitable67,083121,307 00Mixed
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 127 asset managers. All 127 are in the interactive database (link above).

Company's Second Amended and Restated 2018 Stock Incentive Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 114,044,496AGAINST: 4,590,661
Details: description as filed, official tally, votes by 146 asset managers

Description as filed by funds: To approve the second amended and restated 2018 Stock Incentive Plan.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's Second Amended and Restated 2018 Stock Incentive Plan”): 114,044,496 for, 4,590,661 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Company's Second Amended and Restated 2018 Stock Incentive Plan.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 128 asset managers voting on “To approve the second amended and restated 2018 Stock Incentive Plan.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1960 00For
Fidelity13,243,1540 00For
T. Rowe Price5,284,5400 00For
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century0968,978 00Against
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National800,8580 00For
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,21111 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM113,597138,476 00Mixed
MassMutual219,9490 00For
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable188,3900 00For
First Trust179,7980 00For
Victory Capital176,4640 00For

Fund voting reports, all 128 managers: 72,763,815 for, 1,357,401 against, 4,666 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 16 asset managers voting on “To approve the second amended and restated 2018 Stock Incentive Plan.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Orbis Allan Gray Ltd1,319,1950 00For
Cardano Risk Management B.V.27,7730 00For
Erste Asset Management GmbH26,8100 00For
Integral Health Asset Management, LLC10,6460 00For
Genus Capital Management Inc.06,120 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC1,8900 00For
OSSIAM1,5410 00For
Maj Invest Holding A/S5170 00For
Fortitude Family Office, LLC5000 00For
ALGERT GLOBAL LLC4750 00For
ANTIPODES PARTNERS Ltd2900 00For
LEAVELL INVESTMENT MANAGEMENT, INC.00 00--
Boltwood Capital Management300 00For
Ballew Advisors, Inc30 00For
VOISARD ASSET MANAGEMENT GROUP, INC.30 00For
BRANDYWINE OAK PRIVATE WEALTH LLC20 00For

Institutional-manager reports, all 16 managers: 1,389,675 for, 6,120 against, 50 unknown.

In a non-binding advisory vote, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 24 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 111,725,907AGAINST: 6,909,706
Details: description as filed, official tally, votes by 591 asset managers

Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“4. In a non-binding advisory vote, the compensation of the Company's named executive officers”): 111,725,907 for, 6,909,706 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 128 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,802,1951 00For
Fidelity13,243,1540 00For
T. Rowe Price5,145,659138,881 00For
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century0968,978 00Against
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National800,8580 00For
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,2220 00For
Charles Schwab531,7400 00For
Invesco344,41058,830 00Mixed
Prudential/PGIM252,0730 00For
MassMutual219,9490 00For
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable188,3900 00For
First Trust179,7980 00For
Victory Capital176,4640 00For

Fund voting reports, all 128 managers: 72,578,042 for, 1,545,133 against, 4,666 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 490 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group16,859,2240 00For
Fidelity14,080,5860 00For
T. Rowe Price7,715,250220,463 00For
Capital Research Global Investors7,118,3870 00For
BlackRock4,618,8510 00For
Dodge & Cox3,158,8330 00For
Wellington2,943,0190 00For
State Street2,881,1250 00For
GEODE CAPITAL MANAGEMENT, LLC2,282,7700 00For
Winslow Capital Management, LLC2,140,3230 00For
JPMorgan1,988,7770 00For
BAILLIE GIFFORD & CO LTD1,454,2570 00For
American Century01,422,398 00Against
Orbis Allan Gray Ltd1,319,1950 00For
BAILLIE GIFFORD OVERSEAS LTD1,060,1610 00For
Northern Trust758,1350 00For
Nuveen694,4730 00For
Charles Schwab604,5430 00For
Invesco483,86874,557 00Mixed
Legal & General Investment Management Ltd0541,593 00Against
Vanguard523,0690 00For
Two Sigma443,3150 00For
Loomis Sayles436,1750 00For
PICTET ASSET MANAGEMENT SA401,8770 00For
UBS0398,071 00Against

Institutional-manager reports, all 490 managers: 83,480,787 for, 5,500,479 against, 40 abstained, 33,342 not voted, 50 unknown. Showing the 25 largest; every one is in the interactive database (link above).

The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 117,032,947AGAINST: 6,405,215

Prior year: 97.1% for (May 16, 2024 meeting) ▼ 2.3 pts

Details: description as filed, official tally, votes by 134 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“5. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025”): 117,032,947 for, 6,405,215 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 134 asset managers below reported 73,189,416 for, 986,391 against, 4,666 abstained.

FOR
FOR: 73,189,416AGAINST: 986,391ABSTAIN: 4,666
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group17,729,7630 00For
Vanguard15,037,144765,052 00For
Fidelity13,243,1540 00For
T. Rowe Price5,284,5400 00For
BlackRock3,917,4490 00For
Dodge & Cox2,572,1410 00For
AMCAP FUND2,401,9200 00For
NEW ECONOMY FUND1,607,8800 00For
JPMorgan1,384,8360 00For
American Century968,9780 00For
INVESTMENT CO OF AMERICA908,7410 00For
Jackson National800,8580 00For
New York Life734,7030 00For
TIAA684,0000 00For
State Street614,20022 00For
Charles Schwab531,7400 00For
Invesco403,2400 00For
Prudential/PGIM252,0730 00For
MassMutual219,9490 00For
FRANKLIN STRATEGIC SERIES198,3520 00For
Federated Hermes192,8490 00For
CARILLON SERIES TRUST190,4890 00For
Equitable188,3900 00For
First Trust179,7980 00For
Victory Capital176,4640 00For

Showing the 25 largest of 134 asset managers. All 134 are in the interactive database (link above).

Largest ALNYLAM PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 130,311,000 shares outstanding at the time of that meeting.

Fund voting reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 13.61%
2Vanguard 12.13%
3Fidelity 10.16%
4T. Rowe Price 4.06%
5BlackRock 3.01%
6Dodge & Cox 1.97%
7AMCAP FUND 1.84%
8NEW ECONOMY FUND 1.23%
9JPMorgan 1.06%
10American Century 0.74%
Institutional-manager reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 12.94%
2Fidelity 10.81%
3T. Rowe Price 6.09%
4Capital Research Global Investors 5.46%
5BlackRock 3.54%
6Dodge & Cox 2.42%
7Wellington 2.26%
8State Street 2.21%
9GEODE CAPITAL MANAGEMENT, LLC 1.75%
10Winslow Capital Management, LLC 1.64%

Reported ALNYLAM PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ALNYLAM PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)15,309,860 11.75%Form 13F, quarter ended March 31, 2025
Capital World Investors10,916,799 8.38%Schedule 13G, filed May 14, 2026
BlackRock9,559,382 7.34%Form 13F, quarter ended March 31, 2025
Capital Research Global Investors9,471,181 7.27%Schedule 13G, filed May 14, 2026
T. Rowe Price3,505,168 2.69%Form 13F, quarter ended March 31, 2025
State Street3,366,583 2.58%Form 13F, quarter ended March 31, 2025
Wellington Management2,610,986 2.00%Form 13F, quarter ended March 31, 2025
Norges Bank2,292,654 1.76%Form 13F, quarter ended March 31, 2025
JPMorgan Chase2,218,872 1.70%Form 13F, quarter ended March 31, 2025
Invesco913,792 0.70%Form 13F, quarter ended March 31, 2025

Percentages above are of 130,311,000 shares outstanding, as reported by ALNYLAM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ALNYLAM PHARMACEUTICALS INC.'s shareholder meeting held May 8, 2025, in the 2024-2025 proxy season, 591 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 5,798 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — ALNYLAM PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALNYLAM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 13, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALNYLAM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ALNYLAM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ALNYLAM PHARMACEUTICALS (ALNY) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alnylam-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.